- Get in Touch with Us
Last Updated: Apr 25, 2025 | Study Period: 2024-2030
An imaging examination called a magnetic resonance cholangiopancreatography (MRCP) is used to look at the biliary (bile duct) and pancreatic systems. Through an intravenous (IV) line, a dye is injected into the veins for this test.
Magnetic resonance cholangiopancreatography (MRCP) is pronounced col-an-jee-oh pan-kree-at-og-raf-ee. It is a unique kind of MRI that provides precise images of the bile ducts, gallbladder, and pancreas. Then, typically, have an abdominal MRI scan at the same time as the MRCP.
The pancreatic and bile ducts, which are sites where tumours frequently grow, are imaged using computer software during magnetic resonance cholangiopancreatography (MRCP), a specialised type of MRI. Pancreatic cysts and duct obstructions can also be seen with MRCP.
A MRCP can take place concurrently.It typically takes 45 minutes to complete the exam. MRCP procedures can be performed as an outpatient procedure with no hospital stay necessary or as a component of one. MRCP is a non-intrusive procedure.
Invasive procedures include ERCP and PTC. Due to the noninvasive nature of MRCP, procedures like collecting samples or inserting stents which can be carried out during ERCP or PTC are not possible. In order to collect photos, MRCP employs radio waves and a powerful magnetic field.
The contrast substance can occasionally cause some people to have adverse effects. Nausea, headaches, and soreness at the injection site are a few of these that may occur. Hives, irritated eyes, or other adverse reactions to the contrast material in patients are quite uncommon.
The Global magnetic resonance cholangiopancreatography(MRCP) market accounted for $XX Billion in 2023 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2024 to 2030.
Only the central intrahepatic bile ducts, which can be up to 3 mm in diameter and shouldn't be larger than 7 mm, should be visible on an MRCP. Mild biliary dilatation happens in those who have had cholecystectomies, and the CBD can go as big as 10 mm in size.
The portal venous supply system is paralleled by the intrahepatic biliary drainage system.The right posterior duct, which drains posterior segments VI and VII, and the right anterior duct, which drains anterior segments V and VIII, are the two main branches that emerge from the right hepatic duct.
The right posterior duct typically connects to the right anterior duct on its left medial side and runs posterior to it. Segments II through IV are drained by the left hepatic duct, which joins the right hepatic duct to create the common hepatic duct. Segment 1 normally empties into the left or right hepatic duct origin via a different bile duct.
| Sl no | Topic |
| 1 | Market Segmentation |
| 2 | Scope of the report |
| 3 | Abbreviations |
| 4 | Research Methodology |
| 5 | Executive Summary |
| 6 | Introduction |
| 7 | Insights from Industry stakeholders |
| 8 | Cost breakdown of Product by sub-components and average profit margin |
| 9 | Disruptive innovation in the Industry |
| 10 | Technology trends in the Industry |
| 11 | Consumer trends in the industry |
| 12 | Recent Production Milestones |
| 13 | Component Manufacturing in US, EU and China |
| 14 | COVID-19 impact on overall market |
| 15 | COVID-19 impact on Production of components |
| 16 | COVID-19 impact on Point of sale |
| 17 | Market Segmentation, Dynamics and Forecast by Geography, 2024-2030 |
| 18 | Market Segmentation, Dynamics and Forecast by Product Type, 2024-2030 |
| 19 | Market Segmentation, Dynamics and Forecast by Application, 2024-2030 |
| 20 | Market Segmentation, Dynamics and Forecast by End use, 2024-2030 |
| 21 | Product installation rate by OEM, 2023 |
| 22 | Incline/Decline in Average B-2-B selling price in past 5 years |
| 23 | Competition from substitute products |
| 24 | Gross margin and average profitability of suppliers |
| 25 | New product development in past 12 months |
| 26 | M&A in past 12 months |
| 27 | Growth strategy of leading players |
| 28 | Market share of vendors, 2023 |
| 29 | Company Profiles |
| 30 | Unmet needs and opportunity for new suppliers |
| 31 | Conclusion |
| 32 | Appendix |
© 2017-2025 Mobility Foresights Pvt Ltd. All rights reserved.